Chemomab changes CEOs, suspends mid-stage trial; Ex-FDA vaccine official lends more help to Mesoblast
→ There’s a shakeup at the top of Chemomab Therapeutics as the Israeli biotech halts the start of a Phase II study to save cash. In moves that took effect on June 1, co-founder and CSO Adi Mor is running it back as CEO, replacing Dale Pfost, and VP of finance Sigal Fattal has been promoted to CFO. Both Pfost and ex-finance chief Don Marvin were colleagues at Orchid Biosciences and Lodo Therapeutics. To round out these changes, Eliraz Ventures general partner and former OrbiMed Israel venture partner Nissim Darvish has succeeded Pfost as chairman.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.